Searched for
ERBITUX
Alkem Labs to grow chronic therapies, biosimilars to drive future growth: MDAlkem Laboratories, a top-seller of antibiotics, is focusing on the chronic therapy segments and is investing heavily in biosimilars and co...- Lupin Partners Enzene to roll out biosimilar Cetuximab hereIn July 2009, the US Food and Drug Administration (USFDA) approved Eli Lilly and Merck's cetuximab (Erbitux) for treatment of metastatic co...
- Lupin launches biosimilar cetuximab in pact with EnzeneCetuximab has received approval from the Drug Controller General of India (DCGI) for its effectiveness in treating head and neck cancer
- Merck merges pharma, consumer health units; aims to ramp up businessesGoing against the grain: With the unique hybrid model for India, co aims at building scale & ramping up businesses.
- Glenmark rises armed with research after five year hiatusIt may be too early to forecast how Glenmark’s drugs will fare, for the next few years, the generics business will continue to be key.
- Merck KGaA bets on cancer drugs to revitalise German firmMerck KGaA is betting on its oncology pipeline to revitalise the German drugmaker as it sees falling sales from its best-selling medicine, ...
- German drug maker Merck KGaA finds Indian market promising for its pharma, consumer health businessMerck KGaA, the family-controlled $12.5-billion German drug maker, has identified India as one of its key markets under aglobal expansion s...
- Patent protection: Cancer survivors hope that Novartis verdict will help patientsCancer survivors like Lisa Ray are hoping that the SC's rejection of Novartis’ bid to patent a cancer drug will improve the quality of thei...
- Esophageal cancer drug market to double by 2014The esophageal cancer drug market in India will grow from $16 million in 2009 to $36 million in 2014, says a research firm.
- Eli Lilly agrees to buy ImClone for over $6bnThe drugmaker Eli Lilly & Co says it has agreed to buy biotechnology company ImClone Systems Inc. for more than $6 billion in a deal that w...
- ImClone chief, director resign over Icahn takeover rowImClone Systems said its chairman and another director resigned, moving billionaire investor Carl Icahn a step closer to taking control of ...
- Bristol-Myers CEO in hot seat as board meet nearsPeter Dolan, Bristol-Myers Squibb’s embattled chief, spent his summer vacation in France cycling 350 miles in five days.
- Merck launches anti-cancer drug Erbitux in IndiaGlobal pharma major Merck on Friday announced the launch of its colorectal cancer treatment drug 'Erbitux' in India.
- Martha to pay $195,000 to settle SEC chargesHomemaking diva Martha Stewart will pay about $195,000 and cannot serve as the director of a public company for five years.
Load More- Merck merges pharma, consumer health units; aims to ramp up businesses
